Evaxion Biotech A/SEVAX
13F holders, Q4 2025 (December 31)1holders −1
0new positions
1sold out
$4.77avg. 13F price*
At the end of Q4 2025, 1 institutions reported holding Evaxion Biotech A/S (EVAX) in their 13F filings, down 1 from Q3 2025. 0 opened new positions and 1 sold out. The largest holder was Merck & Co., Inc. ($5.8M).
- Company
- Evaxion Biotech A/S
- CUSIP
- 29970R204
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $7 |
All 13F filers, Q3 2025 → Q4 2025: 2 shares sold, net −2 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Merck & Co., Inc. | 2.10% | No change | 1,214,126 | $5.8M |
"% of holder's portfolio" is EVAX's weight in each manager's 13F, not the share of Evaxion Biotech A/S the manager owns.